PTPN1 and obesity disorder: Antibody-trapping of the oxidized form of PTP1B, a highly touted drug target for diabetes and obesity, has been shown to increase insulin signaling in vitro (Stanford and Bottini, 2014; Krishnan et al., 2018; Stanford and Bottini, 2017).